A report released today by H.C. Wainwright about Lexicon Pharma (NASDAQ:LXRX) bumps the target price to $26.00
- Updated: October 6, 2016
Showing a price of $18.50, Lexicon Pharma (NASDAQ:LXRX) traded 0.38% higher on the day. With the last stock price close up 25.36% from the 200-day moving average, compared with the S&P 500 Index which has decreased -0.01% over the same time period. LXRX has recorded a 50-day moving average of $16.86 and a 200-day moving average of $14.76. 534,334 shares of Lexicon Pharma exchanged hands, down from an avg. volume of 865,758
H.C. Wainwright upped the price target of Lexicon Pharma (NASDAQ:LXRX) to $26.00 indicating a potential upside of 0.41%.
Previously on 10/05/2016, Zacks Investment Research released a statement about Lexicon Pharma (NASDAQ:LXRX) raised the target price from $0.00 to $20.00 that suggested an upside of 0.12%.
Recent Performance Chart
With a market capitalization of $0, Lexicon Pharma has one year low of $7.65 and a one year high of $19.62 .
Brief Synopsis On Lexicon Pharma (NASDAQ:LXRX)
Lexicon Pharmaceuticals, Inc. (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company's telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome. LX1032 inhibits tryptophan hydroxylase (TPH), which is an orally-delivered small molecule compound that the Company is developing for the treatment of carcinoid syndrome. Sotagliflozin, or LX4211, which is an orally-delivered small molecule compound that the Company is developing for the treatment of type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound for the treatment of neuropathic pain. The Company's other programs include LX1033, LX2931 and LX7101.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.